Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7450635 | 0.84 | CNR1 (0.40) | CNR1HTTGRM2KDM4EALDH1A1 | |
| SCHEMBL7449475 | 0.84 | PDE1B (0.39) | CNR1HTTGRM2ALDH1A1HPGD | |
| SCHEMBL17507917 | 0.82 | PDE2A (0.42) | GRM2PDE1BPDE2APDE4D | |
| SCHEMBL3087681 | 0.81 | PDE1B (0.55) | GRM2HPGDPDE1BPDE2APDE4D | |
| SCHEMBL7453613 | 0.80 | GRM2 (0.39) | CNR1HTTGRM2HPGDCYP3A4 | |
| SCHEMBL3091849 | 0.76 | PDE1B (0.54) | HPGDPDE1BPDE2A | |
| SCHEMBL676897 | 0.73 | MAOB (0.38) | GRM2TSHRPDE1BPDE2APDE4D | |
| SCHEMBL676359 | 0.73 | PDE1B (0.42) | GRM2ALDH1A1HPGDNPSR1PDE1B | |
| SCHEMBL674937 | 0.72 | PDE1B (0.37) | GRM2HPGDPDE1BPDE2APDE4D | |
| SCHEMBL5402404 | 0.72 | ALDH1A1 (0.40) | HTTGRM2ALDH1A1TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434730-B2 | PDE1 inhibitor compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20130338124-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-2575817-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011153136-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338124-A1 | ORGANIC COMPOUNDS | OPRD1, PDE5A, PDE2A | CNR1 94/4885HTT 3008/4885GRM2 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.